Orchid Pharma Ltd
NSE:ORCHPHARMA

Watchlist Manager
Orchid Pharma Ltd Logo
Orchid Pharma Ltd
NSE:ORCHPHARMA
Watchlist
Price: 1 797.4 INR 4.1% Market Closed
Market Cap: 91.2B INR
Have any thoughts about
Orchid Pharma Ltd?
Write Note

Orchid Pharma Ltd
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Orchid Pharma Ltd
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Orchid Pharma Ltd
NSE:ORCHPHARMA
Net Income (Common)
â‚ą921.7m
CAGR 3-Years
N/A
CAGR 5-Years
6%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Net Income (Common)
â‚ą53.4B
CAGR 3-Years
40%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Net Income (Common)
â‚ą44.8B
CAGR 3-Years
20%
CAGR 5-Years
22%
CAGR 10-Years
15%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Net Income (Common)
â‚ą110.5B
CAGR 3-Years
21%
CAGR 5-Years
21%
CAGR 10-Years
6%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Net Income (Common)
â‚ą18B
CAGR 3-Years
12%
CAGR 5-Years
27%
CAGR 10-Years
8%
M
Mankind Pharma Ltd
NSE:MANKIND
Net Income (Common)
â‚ą19.1B
CAGR 3-Years
15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Orchid Pharma Ltd
Glance View

Market Cap
91.2B INR
Industry
Pharmaceuticals

Orchid Pharma Ltd. engages in the development, manufacture, and marketing of diverse bulk actives, formulations, and nutraceuticals. The company is headquartered in Chennai, Tamil Nadu. The firm is involved in the development, manufacture and marketing of diverse bulk actives, formulations and nutraceuticals. The company has a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardiovascular segment (CVS), nutraceuticals and other oral and sterile products. Its pharmaceutical solutions include active pharmaceutical ingredients (APIs) and finished dosage forms. The company offers APIs, including Cephalosporins-Orals, Cephalosporins-Injectables, Veterinary Products and Non-Antibodies. Its formulations include Cefixime Capsules, Acarbose Tablets, Acarbose Tablets, Clozapime Tablets, Clopidogrel Tablets, Desloratadine Tablets and Cefoperazone and Sulbactam for Injection, among others. Its subsidiaries include Orchid Europe Limited, Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc., and Diakron Pharmaceuticals, Inc., among others.

ORCHPHARMA Intrinsic Value
1 260.63 INR
Overvaluation 30%
Intrinsic Value
Price

See Also

What is Orchid Pharma Ltd's Net Income (Common)?
Net Income (Common)
921.7m INR

Based on the financial report for Mar 31, 2024, Orchid Pharma Ltd's Net Income (Common) amounts to 921.7m INR.

What is Orchid Pharma Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
6%

Over the last year, the Net Income (Common) growth was 99%.

Back to Top